1. Generics Bulletin
  2. >>Business
  3. >>Deals

ANI Strikes Deal With Coeptis For Seven Development-Stage Assets

 
• By Penelope MacRae

Continuing its acquisition streak, ANI Pharmaceuticals has bought a pipeline of seven development-stage generics from Coeptis Pharmaceuticals for $2.3m in cash and up to $12m in development and commercial milestone payments.

Slots_777
ANI’s deal for seven generics has fallen into place • Source: Shutterstock

Specialty pharma player ANI Pharmaceuticals is pressing ahead with its strategy of building out its portfolio through acquisitions, partnerships and internal development. The niche generics-and-brands firm has just purchased a pipeline of seven development-stage generics from Coeptis Pharmaceuticals for $2.3m in cash and up to $12m in development and commercial milestone payments. Citing IQVIA data, ANI said the portfolio “has a combined (estimated) current annual US market value of $1.02bn.”

The newly-acquired portfolio includes three oral and four injectable products. Six of the products are in development at third parties,...

More from Deals

Aurobindo Addresses Rumor Of $5bn Zentiva Buyout

 
• By Dave Wallace

Rumours are circulating that Aurobindo could be set to take ownership of Zentiva from current owner Advent in a $5bn transaction, which would represent one of the largest off-patent sector deals in some time.

$160m War Chest Readied For Aquestive’s Oral Epinephrine Film Launch

 
• By Dean Rudge

Filed through the FDA’s 505(b)(2) hybrid new drug application pathway, Aquestive Therapeutics’ proposed Anaphylm (epinephrine) sublingual film has received major financial backing with a pair of funding deals.

Intas Expands Its Plasma Business With A European Acquisition

 
• By Urtė Fultinavičiūtė

Building on its decade-old plasma division in India, Intas and its subsidiary Accord signed an agreement to acquire one of Europe's largest plasma fractionators Prothya Biosolutions.

Lupin Couples Up With Sandoz For Global Lucentis Biosimilar Deal

 
• By Urtė Fultinavičiūtė

Sandoz snatched commercialization rights to Lupin’s ranibizumab biosimilar across multiple global markets, while also taking steps to decarbonize its operations in Europe.

More from Business

Accord Takes On Ustekinumab Rivals In US With Steepest Discount Yet

 
• By Dave Wallace

Boasting the “lowest WAC price among branded biosimilars to Stelara”, Accord BioPharma has launched its Imuldosa version of ustekinumab in the US at a 92% discount to the blockbuster immunology brand.

Zydus Looks To Ride gIbrance Exclusivity Wave; GLP-1 Battle-Ready With Differentiated Pen

 
• By Vibha Ravi

Ibrance is losing share to other drugs, but Zydus looks forward to a late 2027/early 2028 launch of its generic in the US where partner Synthon might have 180-day exclusivity. In India, as Lilly launches Mounjaro KwikPen, it hopes for a GLP-1 edge with a differentiated device and formulation.

Formycon’s Search For Keytruda Biosimilar Partner Is Key To Deliver FY2025 Guidance

 
• By Urtė Fultinavičiūtė

With H1 revenues not even hitting double-digits, Formycon is bidding on partnerships and royalties to generate at least €46m over the next half-year to reach its revenue goal.